PROTON PUMP INHIBITORS (PPIs) AS FACTORS OF INCREASED RISK OF COVID-19 CORONAVIRAL INFECTION (review)

This work reflects proton pump inhibitors, which today are among the most commonly prescribed drugs in gastroenterology around the world. Impact of PPIs on the severity of the clinical course of COVID-19 infection in patients.
Objective: To determine the effect of PPIs on the severity of the clinical course of COVID-19 infection in patients.
The effect of PPIs on susceptibility to SARS-COV-2. Proton pump inhibitors double the risk of contracting coronavirus infection and are
a contributor to COVID-19 infection.
Analysis of the data obtained showed that PPIs use is associated with an increased risk of a positive test for coronavirus, as already noted. Compared to respondents who do not use these drugs, those who used PPIs once or twice a day

1. Aby E.S., Rodin H., Debes J.D. Proton Pump Inhibitors and Mortality in Individuals With COVID-19. Am J. Gastroenterol. 2020 Nov;115(11):

2. Hajifathalian K., Katz P.O. Regarding "Increased Risk of COVID-19 in Patients Taking Proton Pump Inhibitors". Am J Gastroenterol. 2020 Nov;115(11):

3. Tarlow B., Gubatan J., Khan M.A., Cholankeril G. Are Proton Pump Inhibitors Contributing to SARS-COV-2 Infection? Am J Gastroenterol. 2020 Nov;115(11):

4. Hadi Y.B., Naqvi S.F., Kupec J.T. Risk of COVID-19 in Patients Taking Proton Pump Inhibitors. Am J. Gastroenterol. 2020 Nov;115(11):

5. da Rosa T.F., Foletto V.S., Serafin M.B., Bottega A., Hörner R. Anti-infective properties of proton pump inhibitors: perspectives. Int Microbiol. 2021 Sep 3:1-6.

6. Gubatan J., Zikos T., Spear Bishop E., Wu J., Gottfried A., Becker L., Habtezion A., Neshatian L. Gastrointestinal symptoms and healthcare utilization have increased among patients with functional gastrointestinal and motility disorders during the COVID-19 pandemic. Neurogastroenterol Motil. 2021 Aug 11: e14243.

7. Vaezi M.F., Yang Y.X., Howden C.W. Complications of proton pump inhibitor therapy. Gastroenterology 2017; 153:35–48.

8. Boushey H., Gonda I. Comment on Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. Am J Gastroenterol. 2020 Nov;115(11):

9. Hodges P., Kelly P., Kayamba V. Helicobacter pylori infection and hypochlorhydria in Zambian adults and children: A secondary data analysis. PLoS One. 2021 Aug 27;16(8): e0256487.

10. Lo W.K., Chan W.W. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: A metaanalysis. Clin Gastroenterol Hepatol 2013; 11:483–90.

11. Leonard J., Marshall J.K., Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102:2047–56; quiz 2057.

12. Souza G., Zini N., de Andrade Gandolfi F., Muraro S.P., Luiz Proença-Modena J., Val F.A., Cardoso Melo G., Monteiro W.M., Nogueira M.L., Lacerda MVG, Moraes-Vieira P.M., Nakaya H.I. Acid pH Increases SARS-CoV-2 Infection and the Risk of Death by COVID-19. Front Med (Lausanne). 2021 Aug 20; 8:637885.

13. Bavishi C., Dupont H.L. Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34:1269–81.